Cline Christopher R.
SEC CIK 1943192 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | CFO | 138.0K | — | $4.96M | 34 | 2022-09-01 | 2026-09-15 |
Most active insiders at TVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Dube Eric M | CEO, Dir | — | $41.35M |
| 2 | Heerma Peter | EVP, Chief COMMERCIAL Off | — | $18.97M |
| 3 | ROTE WILLIAM E. | Chief Research Off | — | $16.43M |
| 4 | REED ELIZABETH E | CLO, GC | — | $7.02M |
| 5 | Inrig Jula | EVP, CMO, Head of R, D | — | $5.16M |
| 6 | Cline Christopher R. | CFO | — | $4.64M |
| 7 | Calvin Sandra | SVP, CAO | — | $4.19M |
| 8 | Baynes Roy D. | Dir | — | $2.55M |
| 9 | Meckler Jeffrey A | Dir | — | $1.71M |
| 10 | Coughlin Timothy | Dir | — | $1.27M |
Transactions 34
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-17 21:30 | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | M - OptEx | $17.44 | +20.0K | 138.0K | +17% | +$348.8K |
| DMT | 2026-09-17 21:30 | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $62.34 | -50.5K | 87.5K | -37% | -$3.15M |
| 2026-09-03 16:05 | 2026-09-02 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $66.37 | -642 | 118.0K | -0.5% | -$42.6K | |
| DT | 2026-05-06 20:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | M - OptEx | $0.00 | +4,250 | 121.1K | +4% | $0 |
| DMT | 2026-05-06 20:00 | 2026-05-05+ | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $46.31 | -2,491 | 118.7K | -2% | -$115.4K |
| T | 2026-04-15 21:46 | 2026-04-13 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | A - Grant | $0.00 | +14.0K | 125.2K | +13% | $0 |
| MT | 2026-04-15 21:46 | 2026-04-13+ | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $41.91 | -8,327 | 116.9K | -7% | -$349.0K |
| M | 2026-02-05 | 2026-02-04 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $32.19 | -1,745 | 111.3K | -2% | -$56.2K |
| D | 2026-02-03 | 2026-01-31 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | A - Grant | $0.00 | +28.1K | 120.2K | +31% | $0 |
| D | 2026-02-03 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $32.12 | -7,242 | 113.0K | -6% | -$232.6K |
| D | 2025-12-03 | 2025-12-01 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $35.01 | -20.0K | 92.1K | -18% | -$700.2K |
| D | 2025-12-03 | 2025-12-01 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | M - OptEx | $16.23 | +20.0K | 112.1K | +22% | +$324.6K |
| M | 2025-09-05 | 2025-09-03+ | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $18.51 | -573 | 92.1K | -0.6% | -$10.6K |
| 2025-08-28 | 2025-08-27 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $17.31 | -470 | 92.7K | -0.5% | -$8,136 | |
| D | 2025-05-05 | 2025-05-02 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | M - OptEx | — | +4,920 | 94.9K | +5% | — |
| D | 2025-05-05 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $21.05 | -1,784 | 93.1K | -2% | -$37.6K |
| 2025-04-14 | 2025-04-11 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $13.14 | -48 | 90.0K | -0.1% | -$630.72 | |
| D | 2025-02-04 | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $20.12 | -5,192 | 90.0K | -5% | -$104.5K |
| D | 2025-02-04 | 2025-01-31 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | A - Grant | $0.00 | +21.5K | 95.2K | +29% | $0 |
| 2025-01-23 | 2025-01-22 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $18.94 | -865 | 73.7K | -1% | -$16.4K | |
| 2024-09-09 | 2024-09-09 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $11.52 | -2,490 | 74.6K | -3% | -$28.7K | |
| 2024-09-09 | 2024-09-05 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | A - Grant | $0.00 | +6,750 | 77.1K | +10% | $0 | |
| 2024-09-05 | 2024-09-04 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $9.51 | -514 | 70.3K | -0.7% | -$4,888 | |
| 2024-04-12 | 2024-04-11 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $6.74 | -54 | 70.8K | -0.1% | -$363.96 | |
| D | 2024-02-02 | 2024-02-01 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $8.53 | -3,818 | 70.9K | -5% | -$32.6K |
| D | 2024-02-02 | 2024-01-31 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | A - Grant | $0.00 | +25.0K | 74.7K | +50% | $0 |
| 2024-01-25 | 2024-01-23 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $9.07 | -853 | 49.7K | -2% | -$7,737 | |
| 2023-09-05 | 2023-09-05 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $14.71 | -457 | 50.6K | -0.9% | -$6,722 | |
| 2023-05-12 | 2023-05-10 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $16.59 | -455 | 51.0K | -0.9% | -$7,548 | |
| 2023-04-13 | 2023-04-11 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $21.49 | -47 | 51.5K | -0.1% | -$1,010 | |
| D | 2023-02-02 | 2023-01-31 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | A - Grant | $0.00 | +20.2K | 53.1K | +62% | $0 |
| D | 2023-02-02 | 2023-02-01 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $21.75 | -1,588 | 51.5K | -3% | -$34.5K |
| 2023-01-26 | 2023-01-24 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $21.90 | -852 | 32.9K | -3% | -$18.7K | |
| D | 2022-09-01 | 2022-09-01 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | A - Grant | $0.00 | +5,000 | 33.7K | +17% | $0 |
Purchase Sale Sale after option exercise All abbreviations